Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lucid Diagnostics Inc.LUCD · Entity 6375 | Director | February 20, 2026 | February 24, 2026 |
| PAVmed Inc.PAVM · Entity 7317 | Director | April 02, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lucid Diagnostics Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 235,800 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 123,000 · Balance 235,800 F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed
PAVmed Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,097 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 13,930 · Balance 21,097 F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed, |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed,
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2026 Filed Apr 3, 2026 20:48 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon Stock | 13,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-26-000151 · form4.xml · nonDerivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,097 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed, Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:52 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon Stock | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-26-000078 · form4.xml · nonDerivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,800 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:21 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-25-000045 · form4.xml · nonDerivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 F1 · shares: Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed. F1 · price: Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:46 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon Stock | 112,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003165 · form4.xml · nonDerivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,800 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:49 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001062993-24-004287 · form4.xml · derivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:46 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon stock | 65,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-24-004283 · form4.xml · nonDerivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · price: The issuer granted 65,000 shares of restricted stock to the reporting person pursuant to its long term incentive equity plan. Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:42 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001062993-23-002041 · form4.xml · derivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common stock · 175,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023. Read SEC document |
| January 30, 2023 Filed Feb 3, 2023 01:45 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee stock option (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001062993-23-002044 · form4.xml · derivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common stock · 450,000 shares Expires 2033-01-30 F1 · derivative.exercise_date: One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023. Read SEC document |
| August 02, 2022 Filed Aug 2, 2022 20:41 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001062993-22-017088 · form4.xml · derivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common stock · 80,000 shares Expires 2032-08-02 F1 · derivative.exercise_date: The option vests in 12 quarterly installments, with first installment vesting September 30, 2022. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:22 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee stock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001062993-22-005489 · form4.xml · derivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common stock · 80,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: The option vests in 12 quarterly installments, with first installment vesting March 31, 2022. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:14 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001094891-21-000188 · edgar.xml · derivative · entry 1 White Debra · CIK 0001859882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-04-29 F1 · derivative.exercise_date: The option vests in 12 quarterly installments, commencing on June 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.